CNSP
NASD CNS Pharmaceuticals, Inc.$5.35 ↑ +0.00 (+0.00%) Trading Up from the previous close of $5.35
- YTD change
- +1.90%
- vs 20-day SMA
- +1.02%
- vs 200-day SMA
- +14.93%
Price ranges
Price & Performance
+3.22 (+151.17%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 100.0% away from all-time highs of $192,870.00
- CNSP is up 2% since the beginning of the year
- CNSP is down 47% over the past 12 months
- CNSP is down 7% over the past 1 month
- 0% of all CNSP investors are betting against CNSP
CNSP reads not so good: price sits above both the 20- and 200-day averages, the 12-month move is -46.8%.
- Previous minute
- +$0.00
- Last hour
- +$0.00
- Last 5 days
- +2.09%
- vs 8-day SMA
- +1.53%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
